PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “STREPTODORNASE AND STREPTOKINASE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 469 records · Page 26Linked to original sources
PubMed1983

[Enzymatic debridement of wounds. Comparison of 2 commercial preparations].

In a randomized single-blind trial 44 patients of the Unfallchir. Klinik of Wiesbaden with purulent exudates and/or necrotic substrates in wounds had been enzymatically debrided with preparation A or B (22 patients each group). The solutions had been applied topically in a wet-to-dry technique. Dressings were changed two times a day, until the area became clean and showed granulations. In the group treated with preparation A excellent and good results could be obtained in 16 patients, in the comparison group in 14 patients. Three patients in the group treated with preparation A remained unchanged; in the comparison group five patients remained unchanged or showed deterioration. Due to inefficiency or to side effects treatment was interrupted in four patients of the preparation A-group and in eight patients of the comparison group. The more satisfactory results with preparation A can be interpreted in regard to the action of the enzymes: Fibrinolysin immediately attacks the fibrin of blood clots and fibrinous exudates. Desoxyribonuclease assails desoxyribonucleic acid structures. Streptokinase and streptodornase however are needing plasminogen for transforming it into the effective enzyme of plasmin, as they themselves are uneffective. And the amounts of plasminogen in the treated wounds possibly are not sufficient.

Clinical Trials as Topic↗
PubMedDate not supplied

[Streptokinase].

Explore the source record for details and available documents.

Deoxyribonuclease I↗
PubMed2000

The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema.

Patients with loculated parapneumonic effusion or empyema are sometimes treated with streptokinase or urokinase in an attempt to facilitate pleural fluid drainage by liquefying the pleural exudate and destroying the fibrin membranes producing the loculation. This study evaluated the effectiveness of streptokinase, urokinase, and Varidase (the combination of streptokinase and streptodornase) in liquefying gummy, purulent, exudative material from loculated empyemas. An empyema was created by injecting 10(8) Pasteurella multocida bacteria into the pleural space of New Zealand white rabbits. Twenty specimens, each containing 0.5 g of purulent material obtained 5 days after empyema induction, were placed in test tubes. Streptokinase (15,000 IU), urokinase (10,000 IU), Varidase (4,000-15,000 IU streptodornase + 15,000 IU streptokinase) or saline was added to five sets of four test tubes each. The amount of nonliquefied material that remained after incubation with the fibrinolytic agents was quantitated. Over the 6-h incubation period, the amount of nonliquefied material decreased from 0.5 g to 0.02 g in the Varidase group but never decreased to less than 0.4 g in any of the other three treatment groups. Liquefaction of thick pleural exudates from rabbits with empyema can be achieved with Varidase but not with streptokinase or urokinase.

Animals↗
PubMed1980

Effects of Varidase buccal tablets on the sputum.

Samples of sputum were collected from ten patients with chronic respiratory diseases following treatment with Varidase (streptodornase and streptokinase) buccal tablets, four tablets per day for a period of seven days, and were compared with specimens obtained before the therapy in terms of rheological and cytochemical parameters. The study revealed a tendency for the respiratory secretion to show a lowered yield point and a decrease in mucous fibers after the therapy, thus suggesting, to some extent, the efficacy of the drug as an expectorant.

Adult↗
PubMed1952

[Streptokinase].

Explore the source record for details and available documents.

Deoxyribonuclease I↗
PubMed1981

[Reabsorption of standardised intramuscular haematomas in rabbits treated with streptokinase per os (author's transl)].

Standardised i.m. haematomas in rabbits were studied with and without oral administration of Varidase (containing streptokinase and streptodornase). 125I-fibrinogen was mixed with 2 ml of rabbit blood and reinjected i.m. The standardised haematomas were reabsorbed after 12 to 14 days. During the 3-day administration period of streptokinase the counts measured over the haematoma were even higher than in control animals. As during the therapy a high fibrinolytic activity was found, additional spontaneous bleeding into the haematomas may be suspected. When oral administration of streptokinase was stopped the decrease of counts detected in those animals was significantly accelerated as compared to non-treated animals. This indicates an accelerated reabsorption of those haematomas treated with streptokinase in a low concentration. These results were confirmed by microscopic findings.

Absorption↗